Literature DB >> 33615773

Dual-Targeting Glycol Chitosan/Heparin-Decorated Polypyrrole Nanoparticle for Augmented Photothermal Thrombolytic Therapy.

Ting-Yu Lu1, Chih-Yu Chiang1, Yu-Jui Fan2, Pei-Ru Jheng3, Edgar Daniel Quiñones1, Kuan-Ting Liu1, Shuo-Hsiu Kuo1, Han Yun Hsieh2, Ching-Li Tseng3, Jiashing Yu1, Er-Yuan Chuang3,4.   

Abstract

Near-infrared (NIR)-light-modulated photothermal thrombolysis has been investigated to overcome the hemorrhage danger posed by clinical clot-busting substances. A long-standing issue in thrombosis fibrinolytics is the lack of lesion-specific therapy, which should not be ignored. Herein, a novel thrombolysis therapy using photothermal disintegration of a fibrin clot was explored through dual-targeting glycol chitosan/heparin-decorated polypyrrole nanoparticles (GCS-PPY-H NPs) to enhance thrombus delivery and thrombolytic therapeutic efficacy. GCS-PPY-H NPs can target acidic/P-selectin high-expression inflammatory endothelial cells/thrombus sites for initiating lesion-site-specific thrombolysis by hyperthermia using NIR irradiation. A significant fibrin clot-clearance rate was achieved with thrombolysis using dual-targeting/modality photothermal clot disintegration in vivo. The molecular level mechanisms of the developed nanoformulations and interface properties were determined using multiple surface specific analytical techniques, such as particle size distribution, zeta potential, electron microscopy, Fourier-transform infrared spectroscopy (FTIR), wavelength absorbance, photothermal, immunofluorescence, and histology. Owing to the augmented thrombus delivery of GCS-PPY-H NPs and swift treatment time, dual-targeting photothermal clot disintegration as a systematic treatment using GCS-PPY-H NPs can be effectively applied in thrombolysis. This novel approach possesses a promising future for thrombolytic treatment.

Entities:  

Keywords:  P-selectin; dual targeting; nanoparticle; photothermal thrombolytic treatment; thrombosis

Mesh:

Substances:

Year:  2021        PMID: 33615773     DOI: 10.1021/acsami.0c20940

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

Review 1.  Thrombus-Targeting Polymeric Nanocarriers and Their Biomedical Applications in Thrombolytic Therapy.

Authors:  Qixiao Guan; Hongjing Dou
Journal:  Front Physiol       Date:  2021-11-30       Impact factor: 4.566

2.  Magnet-Guided Bionic System with LIFU Responsiveness and Natural Thrombus Tropism for Enhanced Thrombus-Targeting Ability.

Authors:  Ni Fang; Jia Liu; Jingxin Hou; Yixin Zhong; Ying Luo; Liu Hu; Wenli Zhang; Junrui Wang; Jie Xu; Jun Zhou; Yu Zhang; Haitao Ran; Dajing Guo
Journal:  Int J Nanomedicine       Date:  2022-05-04

3.  Cyclic RGD functionalized PLGA nanoparticles loaded with noncovalent complex of indocyanine green with urokinase for synergistic thrombolysis.

Authors:  Sha Zhang; Jinjie Li; Jiefeng Ren; Zaiyao Xue; Xinlian Qi; Quanjin Si
Journal:  Front Bioeng Biotechnol       Date:  2022-08-10

Review 4.  Research Progress of Photothermal Nanomaterials in Multimodal Tumor Therapy.

Authors:  Xiaolu Shi; Ye Tian; Yang Liu; Zhengrong Xiong; Shaobo Zhai; Shunli Chu; Fengxiang Gao
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

5.  Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy.

Authors:  Zichen Cao; Xinyu Zhang; Zheng Wei; Chuanhui Song; Huihui Zou; Jianchuan Ran; Hongbo Zhang; Diya Xie; Shengwei Han; Yufeng Wang; Yu Cai; Wei Han
Journal:  J Nanobiotechnology       Date:  2022-10-14       Impact factor: 9.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.